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Background: We prospectively investigated the association between different measures of smoking exposure and the risk of
serous, mucinous, and endometrioid ovarian cancers (OC) in a cohort of more than 300 000 Norwegian women.
Methods: We followed 300 398 women aged 19–67 years at enrolment until 31 December 2013 for OC incidence through linkage
to national registries. We used Cox proportional hazards models with attained age as the underlying time scale to estimate
multivariable-adjusted hazard ratios (HRs) with 95% confidence intervals (CIs) adjusted for relevant confounders.
Results: During more than 5.9 million person-years and a median follow-up time of 19 years, 2336 primary invasive (1647, 71%) and
borderline (689, 29%) OC were identified (53% serous, 19% mucinous). Compared with never smokers, current smokers who had
smoked for X10 years had a higher risk of mucinous OC (HR10–19 years vs never¼ 1.73, 95% CI 1.24–2.42; HRX20 vs never¼ 2.26, 95% CI
1.77–2.89, Ptrend o0.001). When stratified by invasiveness, current smokers had a higher risk of invasive mucinous OC (HR¼ 1.78,
95% CI 1.20–2.64) and borderline mucinous OC (HR¼ 2.26 95% CI, 1.71–2.97) (Pheterogeneity¼ 0.34) than never smokers. Smoking
was not associated with serous or endometrioid OC.
Conclusions: Using a very large cohort of women, the current analysis provides an important replication for a similar risk of invasive
and borderline mucinous OC related to smoking.
Cigarette smoking is an established risk factor for mucinous
ovarian cancer (OC) with an estimated population attributable
fraction of 14% (Agudo et al, 2012; International Agency for
Research on Cancer, 2012). Serous (E60%), mucinous (E10%),
endometrioid, and clear cell (both E17%) are the most common
histological subtypes of OC (Kurman et al, 2014). The relationship
between smoking and endometrioid and clear cell OC remains a
controversial topic (Beral et al, 2012; Faber et al, 2013), as results
are not consistent among studies (Terry et al, 2003). A recent
pooled analysis included 51 epidemiological studies and found a
79% increased risk of mucinous OC when comparing participants
who were current and never smokers at study enrolment. This
increased risk was driven by borderline malignant mucinous OC
rather than invasive mucinous tumours (Beral et al, 2012). The
authors found reduced risks of both endometrioid and clear cell
OC, and no association for serous OC, in current smokers. The
pooled analysis did not study the association between OC other
measures of smoking exposure, such as number of cigarettes
smoked per day, smoking duration, pack-years smoked or age at
smoking initiation, and histological subtypes of OC.
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Moreover, few prospective studies have investigated the
association between these measures of smoking exposure and
histological subtypes of OC (Gram et al, 2008; Tworoger et al,
2008; Gram et al, 2012; Licaj et al, 2016; Wentzensen et al, 2016),
and the results of the prospective studies are inconsistent. None of
them found an association between mucinous OC and smoking
duration, and only one (Gram et al, 2012) reported that mucinous
OC was associated with the number of cigarettes smoked per day.
In a recent study (Wentzensen et al, 2016), number of pack-years,
which was the only measure of smoking exposure studied, was
associated with a higher risk of invasive mucinous OC among ever
smokers. Two reports from the same study population found a
positive association between number of cigarettes smoked per day,
smoking duration in years, and the risk of borderline OC (Gram
et al, 2008; Licaj et al, 2016). One reason for the variation in these
results may be the different methods employed to assess and
analyse these measures of smoking exposure.
Thus, there is a need for large prospective studies on the
relationship between smoking and the risk of OC. On the basis of a
cohort of a more than 300 000 Norwegian women, the purpose of
this study was to investigate the role of smoking, including
different measures of smoking exposure, in the risk of different
histological subtypes of OC.
MATERIALS AND METHODS
Study population. The study population has been described
previously (Næss et al, 2008; Bjerkaas et al, 2013). Briefly, it
comprises Norwegian women recruited into different prospective
cohort studies conducted by the Norwegian Institute of Public
Health: the Norwegian Counties Study (1974–1988), the 40 Years
Study (1985–1999), and the Cohort of Norway (CONOR) Study
(1994–2003). All these cohorts are part of the Norwegian Health
Screening Surveys. The response rate in the three studies ranged
from 56 to 88% (Stocks et al, 2010). Overall, 330 342 women were
eligible and 300 398 remained in the analytical cohort after
exclusions due to missing vital status (n¼ 95), prevalent cancer
excluding non-melanoma skin cancer (n¼ 7180), emigration or
death prior to study enrolment, and with inconsistencies in
immigration and/or emigration dates (n¼ 3264). We further
excluded women with missing information on smoking status
(n¼ 2811) and other main covariates included in the analyses
(n¼ 16 594). The present study was approved by the Regional
Committee for Medical Research Ethics South-East, Norway.
Data collection. Smoking status was defined at cohort entry as
never, former, current, or ever smoker. The smoking questions
were similar, across all three cohorts. The questionnaires collected
information on current and former daily smoking habits, smoking
duration, and average number of cigarettes smoked per day. Only
the CONOR Study asked about age at smoking initiation. Thus, in
the other surveys, we calculated this variable for both current (age
at enrolment minus smoking duration in years) and former (age at
enrolment minus years since quitting and smoking duration in
years) smokers.
Information on number of children, age at first childbirth, and
leisure time physical activity was also obtained from the
questionnaires. Number of children was categorised into four
groups (0, 1, 2, and X3), as was age at first childbirth (o20, 20–24,
25–29, and X30 years). Physical activity was categorised into three
groups: low (reading, watching television, and sedentary activity),
moderate (walking, bicycling, or similar activities X4 h per week),
and heavy (light sports or heavy gardening X4 h per week, heavy
exercise or daily competitive sports). The most recent information
regarding education was obtained from Statistics Norway and
used to assign participants to one of the three categories: low
(o10 years), moderate (10–12 years), and high (412 years).
Height and weight were measured at enrolment by a trained
nurse and used to calculate body mass index (BMI), which was
categorised as (o25, 25–29, and X30 kg m 2).
Information on menopausal status was available from ques-
tionnaires. For women with missing age at menopause, 50 years of
age was used as a proxy measure of menopausal status.
Participants were followed for cancer incidence through record
linkage with the Cancer Registry of Norway, and for death and
emigration through linkage to the Norwegian Central Population
Register. These national registries contain correct, detailed,
virtually complete information on cancer incidence and mortality
(Larsen et al, 2009). The International Classification of Diseases
(ICD-7 code 175 or corresponding ICD-9 or ICD-10 codes) and
the World Health Organization’s International Histological
Classification of Tumours were used to identify four histological
subtypes of OC (serous, mucinous, endometrioid, and clear cell)
and to determine invasiveness (borderline and invasive). However,
due to a small number of cases, we chose not to show results for
clear cell OC.
Statistical analysis. Cox proportional hazards models with
attained age as the underlying time scale were used to estimate
multivariable-adjusted hazard ratios (HRs) with 95% confidence
intervals (CI) for the associations between smoking status and OC
overall, for the three histological subtypes we investigated (serous,
mucinous, endometrioid), and for invasiveness of OCs. We then
carried out the same analyses after reclassifying ever smokers
according to different measures of exposure: duration (o10,
10–19, X20 years, and missing n¼ 1795), number of pack-years
(o6, 6–15, X16, and missing n¼ 2707), number of cigarettes
smoked per day (o6, 6–15, X16, and missing n¼ 1587), and age
at smoking initiation (o20, 20–24, X25 years, and missing
n¼ 34 397). For the these analyses, we included missing indicators
after checking that the parameters associated with these indicators
were not statistically significantly associated with risk of OC overall
or by histological subtype. Never smokers were used as the
reference group. The start of the follow-up was defined as age at
enrolment, and exit time as age at any incident cancer diagnosis
(including OC) (except basal cell carcinoma), emigration, death, or
the end of follow-up (31 December 2013), whichever occurred first.
Similar models were used to estimate multivariable-adjusted
HRs with 95% CIs for the association between different measures
of smoking exposure and serous and mucinous OC stratified by
invasiveness. We were not able to do this for endometrioid and
clear cell OC due to small numbers.
Wald w2 statistics were used to test for heterogeneity between
histological subtypes. Models were stratified by cohort study and
birth cohort (p1950 and 41950). If a linear trend was observed
for a specific measure of smoking exposure, that exposure was also
tested as a continuous variable.
Analysis were adjusted for available established risk factors for
OC (World Cancer Research Fund & American Institute for
Cancer Research, 2014). In order to be retained in the final model,
the removal of the covariate had to lead to a change in the
regression coefficients of at least 10% in any of the smoking status
groups. The final model included the covariates: number of
children, age at first childbirth, physical activity level, and BMI.
We did not include use of hormone therapy (information
available for n¼ 89 637) or oral contraceptives (information
available for n¼ 80 736) in the main analyses as this
information was only available in the 40 Years Study and the
CONOR Study. Instead, we performed sensitivity analyses in these
cohorts that included these two covariates. Tests for trend across
categories of measures of smoking exposure were based on the
median value in each category and included never smokers. We
created separate models that included and excluded never smokers.
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We tested if the proportional hazard assumption was met using
Schoenfeld residuals. The modifying effect of number of children,
education, physical activity, BMI, and menopausal status on the
relationship between smoking status and OC was also assessed.
Models with main effects and interaction terms were fitted and
compared with models with only main effects. The difference in
log-likelihood (likelihood ratio test statistics) was compared with a
w2 distribution with degrees of freedom equal to the number of
interaction terms.
All analyses were performed in STATA version 14.0 (StataCorp,
College Station, TX, USA) and in SAS version 9.4 (SAS Institute
Inc., Cary, NC, USA).
RESULTS
Median age at cohort entrance was 41 years. During more than 5.9
million person-years and a median follow-up of 19 years, 2336
cases of primary OC were identified. There were 1242 (53%) serous
OC, 440 (19%) mucinous OC, 190 (8%) endometrioid OC, and 82
(4%) clear cell OC. Altogether 1647 (71%) were diagnosed with
invasive and 689 (29%) with borderline tumours. In this study 38%
of women were current, 21% former, and 41% never smokers at
enrolment. Current smokers had an earlier age at first childbirth,
more often reported low physical activity, had less years of
education when compared with never smokers (Table 1).
When compared with women with serous OC, those with
mucinous OC had an older age at first childbirth, more often
reported low physical activity and were more often overweight
(BMIX 25 kg/m2). Borderline OC was more often seen in obese
(BMIX 30 kg/m2) and nulliparous women when compared with
women with invasive OC (Supplementary Table 1).
Current smokers had a higher risk of all borderline OC but
smoking was not associated with all invasive, serous, or
endometrioid OC (Table 2). No increased risk of mucinous OC
was observed for former smokers, whereas current smokers had a
more than two-fold higher risk (HR¼ 2.09, 95% CI 1.67–2.62)
when compared with never smokers. The elevated risk of mucinous
OC was somewhat lower in ever smokers (HR¼ 1.70, 95% CI
1.37–2.10). Compared with never smokers, current smokers who
had smoked for 10–19 years had a higher risk of mucinous OC
(HR¼ 1.73, 95% CI 1.24–2.42) as did those who smoked for more
than 20 years (HR¼ 2.26, 95% CI 1.77–2.89; Plinear trendo0.001).
We observed a higher risk of mucinous OC among current
smokers who smoked 6–15 pack-years (HR¼ 2.44, 95% CI 1.90–
3.14), those who smoked more than 16 pack-years (HR¼ 1.95,
95% CI 1.41–2.70), those who smoked 6–15 cigarettes per day
(HR¼ 2.18, 95% CI 1.71–2.77), and those who smoked more than
16 cigarettes per day (HR¼ 2.46, 95% CI 1.73–3.50). The risk of
mucinous OC was similar among current smokers who started
smoking before 19 years of age (HR¼ 2.12, 95% CI 1.65–2.72) and
those who started after 20 years of age (HR¼ 1.73, 95% CI 1.24–
2.42). For current smokers, we observed a positive trend between
smoking duration, number of pack-years, number of cigarettes
smoked per day, and age at smoking initiation and the risk of
mucinous OC and all borderline OCs (Table 2). We observed
similar trends with and without never smokers. We found that
each additional year of cigarette smoking increased the risk of
mucinous OCs by 2%. The same elevated risk was found for each
additional cigarette smoked per day.









Mean age at enrolment (95% CI) 43.6 (43.6–43.7) 43.0 (43.0–43.1) 41.7 (41.6–41.7) 42.2 (42.1–42.2)
Number of OC 926 454 956 1410
Number of invasive OC 704 314 629 943
Number of borderline OC 222 140 327 467
Number of serous OC 497 261 484 745
Number of mucinous OC 130 69 241 310
Number of endometrioid OC 90 36 64 100
Number of clear cell OC 40 22 20 42
Number of other OC 169 66 147 213
Arithmetic mean age at diagnosis for OC (95% CI) 58.6 (57.9–59.2) 56.5(55.6–57.4) 55.5 (55.1–56.1) 55.9 (55.4–56.3)
Mean age at diagnosis for invasive (95% CI) 59.5 (58.7–60.2) 57.5 (56.5–58.5) 56.1 (55.4–56.8) 56.6 (56.0–57.1)
Mean age at diagnosis for borderline (95% CI) 55.7 (54.4–57.0) 54.2 (52.6–55.8) 54.5 (53.6–55.4) 54.4 (53.6–55.2)
Mean age at diagnosis for serous (95% CI) 59.1 (58.2–59.9) 56.4 (55.3–57.5) 55.8 (55.1–56.5) 56.0 (55.4–56.6)
Mean age at diagnosis for mucinous (95% CI) 56.9 (55.1–58.8) 55.4 (53.0–57.8) 54.6 (53.5–55.7) 54.8 (53.8–55.8)
Mean age at diagnosis for endometrioid (95% CI) 56.7 (54.6–58.8) 55.0 (52.6–57.4) 54.4 (52.4–56.5) 54.6 (53.1–56.2)
Mean age at diagnosis for clear cells (95% CI) 57.3 (54.0–60.6) 56.2 (52.4–60.1) 56.6 (53.2–60.1) 56.4 (53.9–58.9)
Mean age at diagnosis for other OC (95% CI) 59.8 (58.0–61.5) 58.9 (56.2–61.6) 56.5 (54.9–58.1) 57.3 (55.9–58.7)
Follow-up time in years (age exit and age at
enrolment)
20.1 (20.0–20.1) 18.9 (18.9–19.0) 19.9 (19.8–19.9) 19.5 (19.5–19.6)
Null parity, % 13.2 10.2 11.8 11.2
Mean number of childrena 2.6 (2.6–2.6) 2.4 (2.4–2.4) 2.4 (2.4–2.4) 2.4 (2.4–2.4)
Mean age at first childbirth 25.0 (25.0–25.0) 24.5 (24.4–24.5) 22.9 (22.9–22.9) 23.5 (23.5–23.5)
Physical activity, %
Low 20.3 19.5 25.2 23.1
Middle 58.1 55.8 56.7 56.4
High 21.6 24.7 18.1 20.5
Education in years
Low (o10) 20.0 20.51 32.0 27.9
Moderate(10–12) 51.9 57.34 57.3 57.3
High(X13) 28.1 22.15 10.7 14.8
BMI (kg m 2) 25.0 (24.9–25.0) 25.0 (25.0–25.1) 24.1 (24.0–24.1) 24.4 (24.4–24.4)
Age at smoking initiationb NA 18.3 (18.2–18.3) 20.5 (20.5–20.6) 20.1 (20.0–20.2)
Abbreviations: BMI¼body mass index; CI¼ confidence interval; NA¼ not applicable; OC¼ovarian cancer.
aParous women.
bFor current and former smokers.
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When we stratified serous and mucinous OC by invasiveness
(Table 3), current compared with never smokers were at higher
risk of invasive mucinous OC (HR¼ 1.78, 95% CI 1.20–2.64) and
of borderline mucinous OC (HR¼ 2.26, 95% CI 1.71–2.97). The
test for heterogeneity showed that there was no difference between
invasive and borderline mucinous OC (Pheterogeneity¼ 0.34). We
observed a positive trend between smoking duration and risk of
invasive and borderline mucinous OC, but not for borderline
serous or invasive serous OC (Table 3). The risk for all histological
subtypes of OC was similar in former and never smokers.
We combined three smoking characteristics age at smoking
initiation, duration, and cigarettes smoked per day (Table 4). In
women who smoked for more than 10 years and more than 10
cigarettes per day, the age at smoking initiation (o18 years or older)
had little impact on the risk of mucinous OC when compared with
never smokers. They were HR¼ 1.77 (95% CI 1.26–2.49) and
HR¼ 2.42 (95% CI 1.88–3.10), respectively (Table 4).
We found no statistically significant interactions between
smoking status and number of children, physical activity,
education, or BMI in relation to mucinous or other histological
Table 2. Multivariablea HRs (95% CI) of invasiveness status and by histological subtypes according of OCs according to various
measures of smoking status compared with never smokers 300 398 Norwegian women
All borderlineb All invasiveb Serousc Mucinousc Endometrioidc
ncases HR (95% CI) ncases HR (95% CI) ncases HR (95% CI) ncases HR (95% CI) ncases HR (95% CI)
Smoking status
Never 222 1.00 704 1.00 497 1.00 130 1.00 90 1.00
Former 140 1.23 (0.99–1.52) 314 0.95 (0.83–1.08) 261 1.03 (0.88–1.20) 69 1.09 (0.81–1.47) 36 0.83 (0.56–1.23)
Current 327 1.55 (1.29–1.85) 629 0.97 (0.86–1.08) 484 0.99 (0.87–1.13) 241 2.09 (1.67–2.62) 64 0.74 (0.53–1.03)
Ever 467 1.42 (1.20–1.68) 943 0.96 (0.87–1.06) 745 1.00 (0.89–1.13) 310 1.70 (1.37–2.10) 100 0.77 (0.57–1.04)
Smoking duration in years
Former
p9 56 1.23 (0.91–1.65) 98 0.95 (0.78–1.15) 98 0.99 (0.80–1.23) 26 1.05 (0.68–1.60) 15 0.87 (0.50–1.50)
10–19 56 1.18 (0.87–1.58) 108 0.96 (0.80–1.16) 108 1.04 (0.84–1.28) 28 1.07 (0.71–1.62) 19 1.06 (0.64–1.74)
20þ 25 1.25 (0.82–1.91) 51 0.89 (0.68–1.18) 51 1.13 (0.84–1.52) 13 1.12 (0.63–2.00) 2 0.28 (0.07–1.14)
Ptrend
d 0.07 0.53 0.47 0.04 0.18
Current
p9 18 1.25 (0.74–2.09) 28 0.91 (0.65–1.28) 28 0.95 (0.64–1.42) 13 1.64 (0.90–2.98) 6 1.01 (0.42–2.45)
10–19 64 1.27 (0.95–1.68) 96 0.87 (0.72–1.05) 96 0.85 (0.68–1.07) 51 1.73 (1.24–2.42) 11 0.54 (0.28–1.01)
20þ 243 1.68 (1.38–2.04) 359 1.02 (0.90–1.16) 359 1.04 (0.90–1.21) 175 2.26 (1.77–2.89) 47 0.84 (0.57–1.23)
Ptrend
d o0.001 0.75 0.24 o0.001 0.11
Pack-years
Former
p5 76 1.15 (0.88–1.49) 153 0.98 (0.83–1.15) 153 1.05 (0.87–1.26) 36 0.98 (0.67–1.42) 20 0.79 (0.48–1.28)
6–15 44 1.22 (0.88–1.69) 68 0.84 (0.67–1.05) 68 0.86 (0.67–1.11) 24 1.21 (0.78–1.88) 15 1.11 (0.64–1.93)
16þ 15 1.60 (0.94–2.72) 33 1.11 (0.76–1.62) 33 1.64 (1.14–2.34) 5 0.97 (0.39–2.39) 1 0.31 (0.04–2.24)
Ptrend
d 0.025 0.61 0.89 0.13 0.28
Current
p5 48 1.17 (0.85–1.62) 86 0.86 (0.70–1.05) 86 0.96 (0.76–1.22) 32 1.37 (0.92–2.04) 9 0.52 (0.26–1.06)
6–15 165 1.51 (1.22–1.86) 237 1.03 (0.90–1.18) 237 0.92 (0.78–1.08) 147 2.44 (1.90–3.14) 36 0.83 (0.55–1.24)
16þ 111 1.90 (1.49–2.43) 159 0.96 (0.80–1.15) 159 1.15 (0.95–1.39) 60 1.95 (1.41–2.70) 19 0.88 (0.52–1.48)
Ptrend
d o0.001 0.50 0.84 o0.001 0.29
Number of cigarettes per day
Former
p5 41 1.31 (0.94–1.83) 74 0.97 (0.78–1.20) 74 1.06 (0.83–1.36) 17 0.95 (0.57–1.59) 13 1.1 (0.61–1.98)
6–15 73 1.10 (0.84–1.43) 136 0.92 (0.78–1.09) 136 0.93 (0.77–1.13) 43 1.19 (0.84–1.69) 17 0.67 (0.4–1.14)
16þ 23 1.53 (0.99–2.36) 45 1.03 (0.75–1.42) 45 1.43 (1.05–1.95) 8 1.02 (0.50–2.10) 6 1.11 (0.48–2.55)
Ptrend
d 0.08 0.68 0.29 0.98 0.25
Current
p5 31 1.21 (0.83–1.77) 52 0.80 (0.62–1.03) 52 0.89 (0.67–1.19) 21 1.44 (0.91–2.29) 4 0.38 (0.14–1.05)
6–15 221 1.49 (1.22–1.81) 342 1.02 (0.90–1.16) 342 0.99 (0.85–1.14) 175 2.18 (1.71–2.77) 48 0.82 (0.57–1.19)
16þ 73 2.02 (1.53–2.67) 88 0.94 (0.75–1.17) 88 1.05 (0.83–1.33) 46 2.46 (1.73–3.50) 12 0.89 (0.48–1.65)
Ptrend
d o0.001 0.66 0.81 o0.001 0.28
Age at smoking initiation
Former
20þ 14 1.03 (0.58–1.83) 34 1.16 (0.80–1.68) 34 1.42 (0.97–2.08) 5 0.61 (0.24–1.54) 3 1.10 (0.32–3.80)
p19 37 1.11 (0.75–1.66) 67 1.19 (0.89–1.59) 67 1.18 (0.87–1.59) 20 1.30 (0.75–2.25) 8 1.08 (0.46–2.54)
Ptrend
d 0.04 0.12 0.69 0.51 0.28
Current
20þ 163 1.48 (1.20–1.82) 237 0.95 (0.84–1.09) 237 0.90 (0.77–1.06) 136 2.12 (1.65–2.72) 34 0.72 (0.48–1.09)
p19 163 1.63 (1.30–2.03) 246 1.01 (0.86–1.17) 246 1.11 (0.94–1.32) 105 2.03 (1.53–2.69) 30 0.84 (0.54–1.33)
Ptrend
d o0.001 0.51 0.57 o0.001 0.23
Abbreviations: BMI¼body mass index; CI¼ confidence interval; HR¼ hazard ratios; OC¼ovarian cancer.
aAdjusted for number of children (0, 1, 2, and X3), age at first childbirth (o20, 20–24, 25–29, and X30 years), BMI (o25, 25–29, and X30 kg m 2), and level of physical activity (low, moderate,
and heavy).
bAll histological subtypes.
cInclude invasive and borderline tumours.
dTrend tests include never smokers.
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subtypes of OC. We observed similar higher risks of mucinous OC
when current smokers were compared with never smokers in
analyses stratified by BMI (o25 kg m 2: HR¼ 2.36, 95% CI 1.74–
3.19; 25–29 kg m 2: HR¼ 1.62, 95% CI 1.07–2.44; X30 kg m 2:
HR¼ 2.20, 95% CI 1.17–4.13), but also when stratified by physical
activity and number of children (data not shown).
Table 3. Multivariablea HR (95% CI) of serous and mucinous epithelial OC overall by invasive status according to various measures
of smoking status at enrolment compared with never smokers in 300 398 Norwegian women
Invasive mucinous Borderline mucinous Invasive serous Borderline serous
OCs Ncases N¼138 Ncases N¼302 Ncases N¼888 Ncases N¼354
Smoking status
Never 45 1.00 85 1.00 371 1.00 126 1.00
Former 21 1.01 (0.60–1.70) 48 1.14 (0.80–1.63) 175 0.94 (0.79–1.13) 86 1.27 (0.96–1.67)
Current 72 1.78 (1.20–2.64) 169 2.26 (1.71–2.97) 342 0.94 (0.81–1.10) 142 1.11 (0.86–1.43)
Ever 93 1.49 (1.03–2.16) 217 1.81 (1.40–2.35) 517 0.94 (0.82–1.08) 228 1.17 (0.93–1.47)
Smoking duration in years
Ever smokers
p9 7 0.65 (0.29–1.44) 32 1.42 (0.94–2.15) 88 0.95 (0.75–1.20) 38 1.10 (0.76–1.60)
10–19 27 1.42 (0.88–2.31) 52 1.42 (1.00–2.01) 143 0.90 (0.74–1.09) 61 1.07 (0.79–1.47)
20þ 58 1.89 (1.25–2.86) 130 2.25 (1.68–3.01) 283 0.97 (0.83–1.15) 127 1.25 (0.97–1.63)
Ptrend 0.001 o0.001 0.46 0.12
Pack-years
Ever smokers
p5 19 0.94 (0.55–1.61) 49 1.22 (0.85–1.74) 169 0.98 (0.81–1.18) 70 1.14 (0.85–1.53)
6–15 55 1.96 (1.30–2.96) 116 2.20 (1.65–2.95) 225 0.90 (0.76–1.07) 80 0.92 (0.69–1.22)
16þ 17 1.37 (0.77–2.46) 48 2.05 (1.41–2.96) 118 1.00 (0.80–1.24) 74 1.76 (1.30–2.38)
Ptrend 0.07 0.01 0.35 0.01
Number of cigarettes per day
Ever smokers
p5 11 1.02 (0.52–1.98) 26 1.21 (0.78–1.88) 84 0.89 (0.70–1.12) 42 1.28 (0.90–1.83)
6–15 67 1.68 (1.13–2.49) 151 1.93 (1.46–2.54) 349 0.96 (0.82–1.12) 129 1.00 (0.77–1.29)
16þ 15 1.68 (0.92–3.08) 39 2.18 (1.48–3.23) 80 0.95 (0.74–1.22) 53 1.66 (1.19–2.31)
Ptrend 0.008 o0.001 0.60 0.02
Age at smoking initiation
Ever smokers
25þ 14 1.36 (0.74–2.48) 28 1.61 (1.05–2.48) 78 0.94 (0.74–1.21) 24 0.95 (0.61–1.47)
20–24 32 2.02 (1.27–3.23) 67 2.33 (1.68–3.23) 120 0.88 (0.71–1.08) 49 1.07 (0.76–1.50)
o20 32 1.61 (0.98–2.64) 93 2.12 (1.53–2.92) 213 1.06 (0.88–1.28) 100 1.19 (0.89–1.59)
Ptrend 0.97 0.04 0.27 0.03
Abbreviations: BMI¼body mass index; CI¼ confidence interval; HR¼ hazard ratios; OC¼ovarian cancer.
aAdjusted for number of children (0, 1, 2, and X3), age at first childbirth (o20, 20–24, 25–29, and X30 years), BMI (o25, 25–29, and X30 kg/m2), and level of physical activity (sedentary,
moderate, and heavy).
Table 4. Multivariablea hazard ratios (95% confidence interval) of three combined smoking characteristicsb (duration in years,
number of cigarettes per day and age at start) and serous mucinous and endometrioid tumours in 300 398 Norwegian women
All invasivec All borderlinec Serousd Mucinousd Endometrioidd
Never 704 1.00 222 1.00 497 1.00 130 1.00 90 1.00
Category 1 25 0.73 (0.49–1.09) 18 1.48 (0.91-2.4) 22 0.87 (0.57-1.34) 10 1.47 (0.77-2.82) 4 -
Category 2 10 0.99 (0.53–1.88) 4 – 8 – 1 – 2 –
Category 3 20 0.99 (0.63–1.54) 5 – 13 0.85 (0.49–1.47) 4 – 2 –
Category 4 13 1.38 (0.78–2.44) 6 – 12 1.30 (0.71–2.37) 4 – 1 –
Category 5 132 0.94 (0.78–1.13) 46 1.10 (0.80–1.51) 91 0.93 (0.74–1.17) 34 1.36 (0.93–2.00) 9 –
Category 6 34 0.95 (0.67–1.35) 17 1.13 (0.68–1.87) 28 0.90 (0.61–1.33) 10 1.35 (0.70–2.61) 7 –
Category 7 330 1.00 (0.87–1.14) 178 1.69 (1.38–2.08) 239 0.98 (0.83–1.15) 143 2.42 (1.88–3.10) 35 0.83 (0.55–1.24)
Category 8 166 1.03 (0.85–1.23) 99 1.55 (1.20–2.00) 165 1.20 (0.99–1.45) 56 1.77 (1.26–2.49) 15 0.71 (0.40–1.28)
Category 1: smoked o10 years, o10 years cigarettes per day, age at start X18 years. Category 2: smoked o10 years, o10 years cigarettes per day, age at start o18 years. Category 3: smoked
o10 years, X10 years cigarettes per day, age at start X18 years. Category 4: smoked X10 years, o10 years cigarettes per day, age at start X18 years. Category 5: smoked o10 years, X10
years cigarettes per day, age at start o18 years. Category 6: smoked X10 years, o10 years cigarettes per day, age at start o18 years. Category 7: smoked X10 years, X10 years cigarettes per
day, age at start X18 years. Category 8: smoked X10 years, X10 years cigarettes per day, age at start o18 years.
aAdjusted for number of children (0, 1, 2, X3), age at first childbirth (o20, 20–24, 25–29, X30 years), BMI (o25, 25–29, X30 kg m 2) and level of physical activity (sedentary, moderate, heavy).
bOnly HRs and 95% CI with more than 10 cases are shown.
cAll histological subtypes.
dInclude invasive and borderline tumours.
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We observed no differences in sensitivity analyses that were
additionally adjusted for hormone therapy and oral contraceptive
use (data not shown).
DISCUSSION
In this large, prospective study, cigarette smoking was associated
with invasive and borderline mucinous OC, but not with other
histological subtypes of OC. For invasive and borderline mucinous
OC, we observed a significant, dose–response association with
smoking duration, pack-years, and number of cigarettes smoked
per day. When restricting the analyses to smokers, we found that
each additional year of cigarette smoking and each increase of one
cigarette per day increased the risk of mucinous OC by 2%.
Our study complements the results from two recent pooled
analyses of smoking and OC (Beral et al, 2012; Faber et al, 2013)
that included 14 724 and 28 114 cases of OC, respectively. One was
from a collaborative group on epidemiological studies of OC
including both prospective cohorts and case–control studies and
reported that borderline mucinous (HR¼ 2.25, 95% CI 1.91–2.65)
and invasive mucinous (HR¼ 1.49, 95% CI 1.28–1.73; P for
heterogeneity 0.01) OC incidence were increased when current
smokers were compared with never smokers. This collaborative
study did not include dose–response associations for different
measures of cigarette smoking or for subtypes of OC. The second
pooled analysis studied dose–response associations with different
measures of cigarette smoking, but only included case–control
studies (Faber et al, 2013). Both studies reported lower smoking-
related risks of invasive mucinous OC among current smokers
than we observed in our study. In contrast to the first pooled
analysis of 51 epidemiological studies, our study demonstrated that
smoking increased the risk of both invasive and borderline
mucinous OC to a similar extent. In contrast to the pooled
analysis of 21 case–controls studies (Faber et al, 2013), we did not
find an association between cigarette smoking and risk of
borderline serous OC.
The few prospective cohort studies that have investigated the
association between measure of smoking exposure and the risk of
subtypes of OC (Tworoger et al, 2008; Gram et al, 2012; Licaj et al,
2016) found no association between smoking duration and
mucinous OCs. Each 20 additional pack-years in ever compared
with never smokers was associated with a significant 20% higher
risk of invasive mucinous OC (Wentzensen et al, 2016).
In our study, neither BMI nor education was revealed as an
effect modifier for the association between smoking and histolo-
gical subtypes of OC, as there was no evidence of statistically
significant interaction.
Mucinous OC shares its histological appearance and its
association with smoking with colorectal cancer (Newcomb et al,
1995; Parajuli et al, 2014). As a potential biological mechanism,
somatic mutations in the KRAS gene are common in borderline
tumours but not in invasive epithelial OC, and were found to be
more frequent in borderline mucinous than in borderline serous
OC (Mayr et al, 2006). Cigarette smoking was found to induce
KRAS mutations in patients with lung, pancreatic, and colon
cancers (Diergaarde et al, 2003; Jiao et al, 2007; Baykara et al,
2013). A similar mechanism of oncogenesis might be applicable to
mucinous OC. Adducts of benzo(a)pyrene, a potent local
carcinogen, have been found in ovarian follicular cells of women
exposed to cigarette smoke (Zenzes et al, 1998). The DNA-
damaging effect of adducts might partially explain a biological
plausibility between smoking and mucinous ovarian cancer.
Strengths and limitations. The main strength of this study is the
large number of enrolled women, representing all counties in
Norway, the virtually complete long-term follow-up, the large
number of OC overall, and of histological subtypes of OC. In our
analysis, we stratified the analyses by two birth cohorts (p1950
and 41950), as reproductive and lifestyle factors changed during
follow-up.
The limitations include lack of complete information for
established risk factors such as age at menopause and menarche,
use of oral contraceptives and hormone therapy. The sensitivity
analyses controlling for hormone therapy and oral contraceptive
use cannot be representative of our entire sample and should be
interpreted with caution. The use of HT became more widespread
after 1990 (Bakken et al, 2004), and may be a more important
limitation in younger birth cohorts than it is in our study. In the
recent consortia study by Wentzensen et al (2016), ever use of oral
contraceptive was associated with a lower risk of all invasive OC,
whereas ever use of hormone therapy was associated with a higher
risk; but none of these two factors was associated with invasive
mucinous OC. When we additionally adjusted for hormone
therapy and oral contraceptive in our sensitivity analyses, we
observed similar results.
Another limitation of our study is the possible misclassification
of histological subtypes of OC and invasiveness. We relied on
pathology information recorded by local pathologists. We believe
that a differential misclassification of OC subtypes between current/
former and never smokers is unlikely. In addition, we observe
significant differences between subtype and invasiveness of OC, which
is not supporting significant misclassification in our data.
The prevalence of smoking in Norway continuously decreased
during the follow-up period of this study (1974–2013), but we had
no updated information on smoking status for all participants.
Comparison of OC risk between ever and never smokers gave
similar results as the comparison between current and never
smokers. As only never smokers could change their smoking status
during follow-up (women who quit smoking will still be ever
smokers), misclassification in smoking status in the follow-up
period can be assumed to be low and there is little chance of
misclassification bias, which would tend to attenuate the current
findings. However, the long study period without follow-up
information limits our ability to infer causality. Possible mis-
classification of histological types of OC and invasiveness may also
be present, but we believe that differential misclassification of OC
subtypes between current and never smokers is unlikely.
CONCLUSION
We found a dose–response association between smoking duration,
pack-years, and number of cigarettes smoked per day, and both
invasive and borderline mucinous OC. This large confirmation
study add further evidence that smoking increases the risk of
invasive and borderline mucinous OC to a similar extent.
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Ardanaz E, Khaw KT, Wareham NJ, Key TJ, Allen NE, Trichopoulou A,
Lagiou P, Palli D, Sieri S, Tumino R, Panico S, Boshuizen H, Büchner FL,
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